In 2005, antidepressants generated $19.8 billion in global revenue, with approximately $11.5 billion attributed to depression and the remaining to anxiety and other disorders. The market grew at high double digit rates throughout the 1990s. However, antidepressant sales were down 3.9% in 2005 compared to 2004 due to introduction of generics in recent years and FDA-imposed warnings related to treatment of adolescents. Newer treatments in the pipeline have the potential to fill the marketing void with drugs that have better efficacy and fewer side effects….
